BCR/ABL Quantitative PCR Disease Monitoring
Test Code
P BCR ABLm
Test Synonyms
Philadelphia Chromosome; major t(9;22) e13/e14(p210), minor t(9;22) e1 (p190)
Associations
Chronic myelogenous leukemia (CML), Acute lymphoblastic leukemia (ALL), Allogeneic bone marrow transplantation, Minimal residual disease (MRD), Molecular remission
Methodology
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for BCR/ABL major t(9;22) e13/e14(p210) or minor t(9;22) e1 (p190) fusion gene transcipts.
CPT Codes
83891 – Molecular isolation
83913 - RNA stabilization
83896 x2 – Nucleic acid probe
83898 x2 – Amplification of patient nucleic acid, primer pair
83902 x2 – Reverse transcriptase
83912-26 – Interpretation and report
83913 - RNA stabilization
83896 x2 – Nucleic acid probe
83898 x2 – Amplification of patient nucleic acid, primer pair
83902 x2 – Reverse transcriptase
83912-26 – Interpretation and report
Turnaround Time
3-5 days
Specimen Requirements
- 10.0 mL (min. 9.0 mL) peripheral blood in EDTA
- 5.0 mL (min. 2.5 mL) bone marrow in EDTA
Specimen Stability
- Specimen must be received by MPLN within 48 hours of collection
- Stable at 2-8°C
Storage & Handling
Causes for Rejection
Specimen >48 hours old; Specimen clotted; Specimen stored or shipped at incorrect temperature; Specimen in incorrect anticoagulant; Insufficient specimen volume
Reference Range
Positive: BCR/ABL major or minor fusion quantified relative to ABL and to prior test result
Negative: BCR/ABL major or minor fusion not detected, less than 0.001% BCR/ABL
Negative: BCR/ABL major or minor fusion not detected, less than 0.001% BCR/ABL
Related Content
Cytogenetics
Flow Cytometry
BCR/ABL by FISH
BCR/ABL initial diagnostic workup by quantitative PCR
ABL kinase gene mutation for Gleevec® resistance
Flow Cytometry
BCR/ABL by FISH
BCR/ABL initial diagnostic workup by quantitative PCR
ABL kinase gene mutation for Gleevec® resistance
Description
Molecular detection of the BCR/ABL fusion gene transcript (e13a2, e14a2, e1a2) in patients with a Philadelphia (t[(9;22)(q34;q11.2)]) positive leukemia. The translocation is found in >99% of CML patients, ~20% of adult acute lymphoblastic leukemia (ALL), ~5% of pediatric ALL and ~2% of acute myeloid leukemia (AML).
The primary clinical utilities for BCR/ABL major quantitative PCR testing include (1) the determination of a baseline level of BCR/ABL expression in newly diagnosed CML patients, and (2) the monitoring of patients for molecular evidence of minimal residual disease (MRD) or molecular remission in response to tyrosine kinase inhibitor (TKI) therapy or allogeneic stem cell transplantation.
The primary clinical utilities for BCR/ABL major quantitative PCR testing include (1) the determination of a baseline level of BCR/ABL expression in newly diagnosed CML patients, and (2) the monitoring of patients for molecular evidence of minimal residual disease (MRD) or molecular remission in response to tyrosine kinase inhibitor (TKI) therapy or allogeneic stem cell transplantation.
References
- Jabbour E et al. (2008). Molecular monitoring in chronic myeloid leukemia. Cancer. 112:2112-2118.
Trademarks
Gleevec is a registered trademark of the Novartis Pharmaceuticals Corporation.
